Dyne Therapeutics (NASDAQ:DYN) Issues Earnings Results

Dyne Therapeutics (NASDAQ:DYN) posted its earnings results on Monday. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02, Zacks reports.

Dyne Therapeutics Price Performance

DYN stock traded up $0.57 during trading on Tuesday, reaching $43.64. The company had a trading volume of 962,248 shares, compared to its average volume of 1,591,091. The business has a 50 day moving average of $37.89 and a 200 day moving average of $30.32. The company has a market cap of $3.81 billion, a P/E ratio of -10.77 and a beta of 1.07. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $45.46.

Insiders Place Their Bets

In related news, COO Susanna Gatti High sold 10,163 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Oxana Beskrovnaya sold 30,426 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $32.96, for a total value of $1,002,840.96. Following the sale, the insider now directly owns 149,647 shares of the company’s stock, valued at approximately $4,932,365.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 202,133 shares of company stock worth $6,500,387. Company insiders own 20.77% of the company’s stock.

Analysts Set New Price Targets

DYN has been the subject of several analyst reports. Oppenheimer restated an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research note on Monday, May 6th. Piper Sandler raised their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday. HC Wainwright upped their target price on shares of Dyne Therapeutics from $48.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Finally, Morgan Stanley assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.56.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.